A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Investigational medicinal product(s)
INFLIXIMABBNT327 20 mg mlCISPLATINBNT327 50 mg mlPEMETREXEDPACLITAXELCARBOPLATINAnti-CCR8 NF mAbEntyvio 300 mg powder for concentrate for solution for infusion
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
Main endpoint is the Objective Response Rate (ORR) assessed by the Investigator (the study doctor).
Endpoint detail
Endpoints include incidence of all adverse events (AEs), including AEs leading to discontinuation, and death (per CTCAE v5.0) and additional anti-tumor efficacy parameters, such as PFS, DOR, and TTR as assessed by the Investigator and OS. Doctors will measure the size of the tumors using special rules called RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.